The START Center
Welcome,         Profile    Billing    Logout  
 11 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jimenez, Isabel
TWT-101, NCT04521413: Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Recruiting
1/2
170
Canada, US, RoW
CFI-402411, 2411, 402411, Pembrolizumab, Keytruda, pembro
Treadwell Therapeutics, Inc, TIO Discovery Engine
Advanced Solid Malignancies
11/24
12/24
NCT06244992: PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
68
US
PTT-936, Combination of PTT-936 and anti-PD-1/L1 therapy
Pyrotech Therapeutics, Inc.
Locally Advanced or Metastatic Solid Tumors
12/25
02/26
KEYNOTE-B47, NCT04130516: Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab

Recruiting
1/2
200
US
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody, KEYTRUDA®, Pembrolizumab
Linnaeus Therapeutics, Inc., Merck Sharp & Dohme LLC
Solid Tumor, Adult
12/26
12/27
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
190
Europe, US
ASTX029
Taiho Oncology, Inc.
Solid Tumor, Adult
08/24
12/25
PMD-026-1-001, NCT04115306: Phase 1/1b/2 Study of Oral PMD-026 in Patients with Metastatic Breast Cancer

Recruiting
1/2
61
US
PMD-026, fulvestrant, Faslodex
Phoenix Molecular Designs
Metastatic Breast Cancer
12/25
03/26
BBI-20201001, NCT04278144 / 2021-006812-10: A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Active, not recruiting
1/2
175
Europe, US, RoW
BDC-1001, Nivolumab, Opdivo
Bolt Biotherapeutics, Inc., Bristol-Myers Squibb
HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
01/25
01/26
KB-0742-1001, NCT04718675: A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Active, not recruiting
1/2
280
Europe, US
KB-0742
Kronos Bio
Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC, Platinum Resistant High Grade Serous Ovarian Cancer
12/25
12/25
SNS-101-2-1, NCT05864144: A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Recruiting
1/2
169
US
SNS-101 (anti-VISTA), Cemiplimab
Sensei Biotherapeutics, Inc., Regeneron Pharmaceuticals
Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
06/27
06/27
SGNCEA5C-001, NCT06131840: A Study of PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors

Recruiting
1
410
Europe, Canada, US
PF-08046050, SAR445953; SGN-CEACAM5C
Seagen Inc., Sanofi
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
03/30
03/30
STC15-22101, NCT05584111: Oral Administration of STC-15 in Subjects With Advanced Malignancies

Active, not recruiting
1
42
US
STC-15, METTL-3 Inhibitor
STORM Therapeutics LTD
Advanced Cancer, Advanced Solid Tumor, Cancer
12/24
03/25
QTX3034-001, NCT06227377: QTX3034 in Patients With KRAS G12D Mutation

Recruiting
1
250
US
QTX3034, Cetuximab
Quanta Therapeutics
Solid Tumors
04/27
04/27
NCT06428500: QTX3046 in Patients with KRAS G12D Mutations

Recruiting
1
240
US
QTX3046, Cetuximab
Quanta Therapeutics
Advanced Solid Tumor
07/27
07/27
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
824
Europe, US, RoW
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
11/26
02/28
NCT06466187: A Study of PF-08052666/SGN-MesoC2 in Advanced Solid Tumors

Recruiting
1
365
US
PF-08052666, HBM9033; SGN-MesoC2
Seagen Inc.
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
11/28
11/28
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
SGNB7H4V-001, NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Active, not recruiting
1
572
Europe, Canada, US
SGN-B7H4V, Pembrolizumab, Keytruda
Seagen Inc.
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
11/27
11/27
SGNPDL1V-001, NCT05208762: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Recruiting
1
438
Europe, Canada, US
PF-08046054, SGN-PDL1V, pembrolizumab, Keytruda
Seagen Inc.
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Melanoma, Triple Negative Breast Neoplasms, Gastric Cancer
07/25
12/27
ADRX-0706-001, NCT06036121: A Study of ADRX-0706 in Select Advanced Solid Tumors

Recruiting
1
144
US, RoW
ADRX-0706
Adcentrx Therapeutics
Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
09/25
12/26
NCT05702424: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Completed
1
14
US
IGM-7354
IGM Biosciences, Inc.
Solid Tumor
05/24
05/24

Download Options